Dr. David R. Carr, M.D.
Mohs Surgery (MOHS-Micrographic Surgery Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 283
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Ohio State University College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
OH license 35.094116 -
Dermatology Physician
OH license 35.094116
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 283
- Services billed
- 1,150
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 304 | 245 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 163 | 108 |
| Established patient office or other outpatient visit, 20-29 minutes | 132 | 105 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 82 | 82 |
| Destruction of precancer skin growth, 2-14 growths | 66 | 11 |
| Biopsy of related skin growth, first growth | 59 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 30 |
| Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | 35 | 31 |
| Destruction of precancer skin growth, 1 growth | 34 | 22 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $2,338 in total to this clinician.
| F. Hoffmann-la Roche AG | $2,338 |
|---|
| Consulting Fee | $2,273 |
|---|---|
| Food and Beverage | $65.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| F. Hoffmann-la Roche AG Dec 3, 2025 | Consulting Fee | $1,768 |
| F. Hoffmann-la Roche AG Oct 28, 2025 | Consulting Fee | $505 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $147,762 in research payments for these studies, mostly to the institutions running them.
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03969004
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.